Weill Cornell Medicine and New York Genome Center researchers, in collaboration with Oxford Nanopore Technologies, have developed a new method to assess on a large scale the three-dimensional structure of the human genome, or how the genome folds.
With a generous gift of $10 million from Board of Fellows member Alan Hartman and his wife, Kim, Weill Cornell Medicine will establish a multidisciplinary research institute to advance organ regeneration and repair.
Dr. Sheila Nirenberg, the Nanette Laitman Professor of Neurology and Neuroscience and a professor of physiology and biophysics at Weill Cornell Medicine, has received the Barbara McClintock Women Innovator Award at the Inaugural Women Innovator Awards.
A new preclinical study by Weill Cornell Medicine investigators shows that one specific set of antibodies that is induced naturally by gut beneficial bacteria can be transferred from mothers to infants through breast milk and help infants defend against infection-induced diarrheal illness.
A promising venture that hopes to develop a new drug therapy for colorectal cancer won $50,000 in funding and recognition from experienced venture capitalists on May 26 at the annual Biomedical Business Plan Challenge.
Genetically engineered immune cells successfully target the specific cancer cells that may be responsible for relapse of acute myeloid leukemia, a type of blood cancer, and proved effective in animal models of the disease.
Researchers at Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center have identified a previously unrecognized form of hormone therapy-resistant prostate cancer, as well as a set of molecules that drive its growth. This discovery opens the door to the development of therapies that treat this specific disease.
DNA mutations are essential to the rapid development of an array of antibody-producing immune cells called B cells that collectively can recognize a vast number of specific targets. But this process can go awry in people with a mutation in a gene called SETD2, leading to a type of aggressive blood cancer.
More than 400 students celebrated a milestone on May 19: graduating from Weill Cornell Medical College and Weill Cornell Graduate School of Medical Sciences.
The award recognizes alumni for their outstanding contributions to biomedical research in education, focusing on science and scholarship, leadership, mentoring and teaching, and service to society.
The award honors an alumnus who has demonstrated outstanding achievement in research, education or patient care, and has brought acclaim to the institution.
Dr. Denise Howard, a leading obstetrician and gynecologist who specializes in gynecologic surgery and women’s reproductive health, has been appointed chief of the Department of Obstetrics and Gynecology at NewYork-Presbyterian Brooklyn Methodist Hospital.
Weill Cornell Medicine-Qatar awarded Cornell University medical degrees to 41 new doctors on May 11 during the college’s first graduation ceremony held in person since the beginning of the COVID-19 pandemic.
Tumors can force neighboring cells into supporting cancer growth by releasing lactate into their local environment, according to researchers at Weill Cornell Medicine.
Immunotherapy unleashes the power of the immune system to fight cancer. However, for some patients, immunotherapy doesn’t work, and new research may help explain why.
Weill Cornell Medicine researchers have identified a protein in Mycobacterium tuberculosis (Mtb) that contributes to drug tolerance, a phenomenon that allows bacteria to survive treatment with drugs that would normally kill them.
A protein called CDC7, long thought to play an essential role early in the cell division process, is in fact replaceable by another protein called CDK1, according to a study by investigators at Weill Cornell Medicine and the Dana-Farber Cancer Institute.
